Royce & Associates LP Cuts Stock Holdings in Hims & Hers Health, Inc. (NYSE:HIMS)

Royce & Associates LP reduced its position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 55.1% in the 4th quarter, HoldingsChannel reports. The firm owned 153,000 shares of the company’s stock after selling 188,000 shares during the period. Royce & Associates LP’s holdings in Hims & Hers Health were worth $3,700,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Crewe Advisors LLC acquired a new position in Hims & Hers Health during the fourth quarter worth about $28,000. Raleigh Capital Management Inc. grew its position in Hims & Hers Health by 1,100.0% during the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after buying an additional 1,100 shares during the period. Blume Capital Management Inc. grew its position in Hims & Hers Health by 100.0% during the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after buying an additional 600 shares during the period. Smartleaf Asset Management LLC grew its position in Hims & Hers Health by 4,415.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company’s stock worth $36,000 after buying an additional 1,413 shares during the period. Finally, US Bancorp DE grew its position in Hims & Hers Health by 346.7% during the fourth quarter. US Bancorp DE now owns 1,943 shares of the company’s stock worth $47,000 after buying an additional 1,508 shares during the period. 63.52% of the stock is owned by hedge funds and other institutional investors.

Hims & Hers Health Stock Performance

Shares of NYSE HIMS opened at $33.85 on Thursday. Hims & Hers Health, Inc. has a 1 year low of $11.20 and a 1 year high of $72.98. The firm’s 50 day moving average price is $38.88 and its 200 day moving average price is $28.52. The firm has a market cap of $7.52 billion, a P/E ratio of 76.94 and a beta of 1.37.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.09 by $0.02. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The firm had revenue of $481.14 million for the quarter, compared to analyst estimates of $494.56 million. As a group, equities analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the stock. Bank of America upped their target price on shares of Hims & Hers Health from $21.00 to $22.00 and gave the stock an “underperform” rating in a research report on Tuesday. Needham & Company LLC upped their target price on shares of Hims & Hers Health from $31.00 to $61.00 and gave the stock a “buy” rating in a research report on Tuesday, February 25th. BTIG Research initiated coverage on shares of Hims & Hers Health in a research report on Tuesday, January 7th. They set a “buy” rating and a $35.00 target price on the stock. Canaccord Genuity Group increased their price target on shares of Hims & Hers Health from $38.00 to $68.00 and gave the company a “buy” rating in a research report on Wednesday, February 19th. Finally, Citigroup reiterated a “sell” rating and issued a $27.00 price target on shares of Hims & Hers Health in a research report on Thursday, March 6th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $37.31.

Insider Buying and Selling

In other Hims & Hers Health news, CFO Oluyemi Okupe sold 18,959 shares of the stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $25.77, for a total transaction of $488,573.43. Following the transaction, the chief financial officer now owns 132,578 shares of the company’s stock, valued at $3,416,535.06. This trade represents a 12.51 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Patrick Harrison Carroll sold 23,287 shares of the stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $34.31, for a total transaction of $798,976.97. Following the transaction, the insider now directly owns 209,661 shares in the company, valued at approximately $7,193,468.91. This represents a 10.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 1,034,506 shares of company stock worth $36,635,024. 17.71% of the stock is owned by insiders.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.